LONG BEACH, Calif. — In this video from the American Society of Retina Specialists annual meeting, Charles C. Wykoff, MD, PhD, FASRS, discusses sozinibercept combination therapy in the phase 3 ShORe and COAST trials.
The primary endpoint was not met in either study, which combined sozinibercept (Opthea) with ranibizumab or aflibercept for the treatment of neovascular age-related macular degeneration.
“This was a robust phase 3 clinical trial program involving nearly 2,000 patients,” Wykoff, of Retina Consultants of Texas, told Healio. “In this program, sozinibercept in